Control Bionics Ltd (AU:CBL) — Market Cap & Net Worth
Market Cap & Net Worth: Control Bionics Ltd (CBL)
Control Bionics Ltd (AU:CBL) has a market capitalization of $23.82 Million (AU$33.67 Million) as of September 20, 2026. Listed on the AU stock exchange, this Australia-based company holds position #24646 globally and #1006 in its home market, demonstrating a 3.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Control Bionics Ltd's stock price AU$0.06 by its total outstanding shares 543088709 (543.09 Million). Also see CBL asset base for a full breakdown of the balance sheet.
Control Bionics Ltd Market Cap History: 2020 to 2026
Control Bionics Ltd's market capitalization history from 2020 to 2026. Data shows change from $325.78 Million to $23.82 Million (-38.83% CAGR). Also see how efficiently does Control Bionics Ltd generate cash for how efficiently the company converts equity into cash flow.
Control Bionics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Control Bionics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Control Bionics Ltd stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.92x
Control Bionics Ltd's market cap is 4.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $325.78 Million | $4.09 Million | -$3.55 Million | 79.68x | N/A |
| 2021 | $147.29 Million | $4.50 Million | -$6.11 Million | 32.72x | N/A |
| 2022 | $57.18 Million | $5.64 Million | -$5.63 Million | 10.13x | N/A |
| 2023 | $17.68 Million | $5.35 Million | -$5.91 Million | 3.30x | N/A |
| 2024 | $23.06 Million | $6.14 Million | -$6.11 Million | 3.75x | N/A |
| 2025 | $23.44 Million | $4.77 Million | -$7.27 Million | 4.92x | N/A |
Competitor Companies of CBL by Market Capitalization
Companies near Control Bionics Ltd in the global market cap rankings as of September 20, 2026. Review Control Bionics Ltd (CBL) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Control Bionics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Control Bionics Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Control Bionics Ltd's market cap moved from $325.78 Million to $ 23.82 Million, with a yearly change of -38.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$23.82 Million | +1.64% |
| 2025 | AU$23.44 Million | +1.67% |
| 2024 | AU$23.06 Million | +30.43% |
| 2023 | AU$17.68 Million | -69.09% |
| 2022 | AU$57.18 Million | -61.18% |
| 2021 | AU$147.29 Million | -54.79% |
| 2020 | AU$325.78 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Control Bionics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.82 Million USD |
| MoneyControl | $23.82 Million USD |
| MarketWatch | $23.82 Million USD |
| marketcap.company | $23.82 Million USD |
| Reuters | $23.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more